For the Inventor, By the Inventor

Enter assignee name

Carmiel, Israel

Protalix Ltd.

Calculating rank

USPTO Granted Patents = 27

% Expired Patents = 29.6

CIPO Patents = 2

EPO Patents = 20

Trademarks = 1

Forward Citations = 100

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Yoseph Shaaltiel (23 out of 23 patents)

Avidor Shulman (11 out of 19 patents)

Tali Kizhner (11 out of 11 patents)

4. Ilya Ruderfer (10 out of 10 patents)

5. Uri Hanania (9 out of 9 patents)

6. Gideon Baum (8 out of 12 patents)

7. Sharon Hashmueli (7 out of 7 patents)

8. Daniel Bartfeld (7 out of 7 patents)

9. Ayala Lewkowicz (6 out of 8 patents)

10. Talia Shekhter (5 out of 5 patents)

11. Yaniv Azulay (5 out of 5 patents)

12. Liat Fux (4 out of 4 patents)

13. Tehila Ben-Moshe (4 out of 9 patents)

14. Svetlana Gingis-Velitski (3 out of 3 patents)

15. Tami Ariel (3 out of 3 patents)

Core Competencies:

Uric Acid Treatment

Stabilized Alpha-Galactosidase

Modified DNase

Chimeric Polypeptides

Plant Cell Culture

Therapeutic Regimen

High Mannose Proteins

TNFalpha Inhibitor

Nucleic Acid Constructs

Inhalable Formulations

Saccharide-Conjugates

Lysosomal Proteins

27 patents: Sort by Forward Citations

1. 12703857 - METHODS OF TREATING DISEASES ASSOCIATED WITH ELEVATED URIC ACID (2026-08-11),

2. 12674146 - MODIFIED URICASE AND USES THEREOF (2026-07-07),

3. 12385054 - Removal of constructs from transformed cells (2025-08-12),

4. 12385026 - Stabilized alpha-galactosidase and uses thereof (2025-08-12),

5. 12194079 - Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase (2025-01-14),

6. 11814657 - Modified DNase and uses thereof (2023-11-14),

7. 11225648 - Modified DNase and uses thereof (2022-01-18),

8. 10870842 - Stabilized alpha-galactosidase and uses thereof (2020-12-22),

9. 10730925 - Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same (2020-08-04),

10. 10364413 - Large scale disposable bioreactor (2019-07-30),

11. 10280414 - Stabilized α-galactosidase and uses thereof (2019-05-07),

12. 10087232 - Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy (2018-10-02),

13. 10000551 - Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same (2018-06-19),

14. 9732333 - Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells (2017-08-15),

15. 9708595 - Stabilized alpha-galactosidase and uses thereof (2017-07-18),

Company Overview

Protalix Ltd. is a biopharmaceutical company based in Carmiel, Israel, specializing in the development and commercialization of innovative therapies derived from its proprietary plant cell-based protein expression system. The company focuses on producing therapeutic proteins for various medical conditions, including rare diseases. Protalix aims to address unmet medical needs through its advanced biotechnological approaches, leveraging its expertise in protein production and formulation to enhance patient outcomes globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

27 Patents

#1 in Carmiel

#225 in Israel

#24,089 in the World

Carmiel, Israel

Protalix Ltd.

Forward Citations = 100

46 inventors:

Yoseph Shaaltiel (23 out of 23 patents)

Avidor Shulman (11 out of 19 patents)

Tali Kizhner (11 out of 11 patents)

4. Ilya Ruderfer (10 out of 10 patents)

5. Uri Hanania (9 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Protalix Ltd.. Retrieved from https://idiyas.com/company/protalix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…